pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

24,843 catalysts · 5,198 approval · 5,000 device 510k · 4,728 grant · 3,126 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 97 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2023-06-08×clear all
type
  • approval5,198
  • device 510k5,000
  • grant4,728
  • 8k filing3,126
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings583
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Jul 17, 2023

    1
    ›Jul 21, 2023approval1118d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗

    Week of Jul 24, 2023

    24
    ›Jul 24, 2023approval1115d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

    Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 24, 2023approval1115d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

    Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 24, 2023approval1115d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

    Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 26, 2023approval1113d agoSERTRALINE HYDROCHLORIDE — FDA approvalSERTRALINE HYDROCHLORIDE

    Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL

    full page →SERTRALINE HYDROCHLORIDE →fda approvals ↗
    ›Jul 26, 2023approval1113d agoSERTRALINE HYDROCHLORIDE — FDA approvalSERTRALINE HYDROCHLORIDE

    Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL

    full page →SERTRALINE HYDROCHLORIDE →fda approvals ↗
    ›Jul 26, 2023approval1113d agoTIVDAK (TISOTUMAB VEDOTIN-TFTV) — FDA approvaltisotumab vedotin

    Sponsor: SEAGEN. Form: INJECTABLE. Route: INJECTION

    full page →tisotumab vedotin →fda approvals ↗
    ›Jul 26, 2023approval1113d agoHIBICLENS (CHLORHEXIDINE GLUCONATE) — FDA approvalCoorg Instituite of Dental Sciences

    Sponsor: MOLNLYCKE HLTH. Form: SOLUTION. Route: TOPICAL

    full page →fda approvals ↗
    ›Jul 28, 2023approval1111d agoCINACALCET HYDROCHLORIDE — FDA approvalCINACALCET HYDROCHLORIDE

    Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

    full page →CINACALCET HYDROCHLORIDE →fda approvals ↗
    ›Jul 28, 2023approval1111d agoZEPZELCA (LURBINECTEDIN) — FDA approvallurbinectedin

    Sponsor: JAZZ. Form: POWDER. Route: INTRAVENOUS

    full page →lurbinectedin →fda approvals ↗
    ›Jul 28, 2023approval1111d agoLOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Jul 28, 2023approval1111d agoLOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Jul 28, 2023approval1111d agoMOUNJARO (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗
    ›Jul 28, 2023approval1111d agoMOUNJARO (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗

    Week of Jul 31, 2023

    10
    ›Jul 31, 2023approval1108d agoARTESUNATE — FDA approvalARTESUNATE

    Sponsor: AMIVAS. Form: POWDER. Route: INTRAVENOUS

    full page →ARTESUNATE →fda approvals ↗
    ›Jul 31, 2023approval

    Week of Aug 7, 2023

    8
    ›Aug 8, 2023approval1100d agoVORICONAZOLE — FDA approvalVORICONAZOLE

    Sponsor: CADILA. Form: TABLET. Route: ORAL

    full page →VORICONAZOLE →fda approvals ↗
    ›Aug 8, 2023approval

    Week of Aug 14, 2023

    7
    ›Aug 14, 2023approval1094d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Aug 14, 2023approval
    ← prev
    page 3 of 497
    next →
    1108d ago
    LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: LUPIN LTD. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Aug 3, 2023approval1105d agoTRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalTRIKAFTA (COPACKAGED)

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →TRIKAFTA (COPACKAGED) →fda approvals ↗
    ›Aug 3, 2023approval1105d agoTRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalTRIKAFTA (COPACKAGED)

    Sponsor: VERTEX PHARMS INC. Form: GRANULES. Route: ORAL

    full page →TRIKAFTA (COPACKAGED) →fda approvals ↗
    ›Aug 3, 2023approval1105d agoORKAMBI (IVACAFTOR) — FDA approval(ivacaftor + lumacaftor)

    Sponsor: VERTEX PHARMS INC. Form: GRANULE. Route: ORAL

    full page →(ivacaftor + lumacaftor) →fda approvals ↗
    ›Aug 3, 2023approval1105d agoKALYDECO (IVACAFTOR) — FDA approvalVertex, Inc.

    Sponsor: VERTEX PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 3, 2023approval1105d agoKALYDECO (IVACAFTOR) — FDA approvalivacaftor

    Sponsor: VERTEX PHARMS INC. Form: GRANULE. Route: ORAL

    full page →ivacaftor →fda approvals ↗
    ›Aug 3, 2023approval1105d agoORKAMBI (IVACAFTOR) — FDA approval(ivacaftor + lumacaftor)

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →(ivacaftor + lumacaftor) →fda approvals ↗
    ›Aug 3, 2023approval1105d agoSYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approvalivacaftor

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →ivacaftor →fda approvals ↗
    ›Aug 4, 2023approval1104d agoIZERVAY (AVACINCAPTAD PEGOL SODIUM) — FDA approvalavacincaptad pegol sodium

    Sponsor: ASTELLAS. Form: SOLUTION. Route: INTRAVITREAL

    full page →avacincaptad pegol sodium →fda approvals ↗
    1100d ago
    VORICONAZOLE — FDA approvalVORICONAZOLE

    Sponsor: CADILA. Form: TABLET. Route: ORAL

    full page →VORICONAZOLE →fda approvals ↗
    ›Aug 8, 2023approval1100d agoZIPRASIDONE MESYLATE — FDA approvalZIPRASIDONE MESYLATE

    Sponsor: GLAND. Form: POWDER. Route: INTRAMUSCULAR

    full page →ZIPRASIDONE MESYLATE →fda approvals ↗
    ›Aug 9, 2023approval1099d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

    Sponsor: NOVITIUM PHARMA. Form: TABLET. Route: ORAL

    full page →ACETAZOLAMIDE →fda approvals ↗
    ›Aug 9, 2023approval1099d agoTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalteclistamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →teclistamab →fda approvals ↗
    ›Aug 9, 2023approval1099d agoTALVEY (TALQUETAMAB-TGVS) — FDA approvaltalquetamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →talquetamab →fda approvals ↗
    ›Aug 9, 2023approval1099d agoGAVRETO (PRALSETINIB) — FDA approvalRIGEL PHARMACEUTICALS INC

    Sponsor: RIGEL PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 11, 2023approval1097d agoAKEEGA (ABIRATERONE ACETATE) — FDA approval(abiraterone acetate + niraparib)

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →(abiraterone acetate + niraparib) →fda approvals ↗
    1094d ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Aug 14, 2023approval1094d agoELREXFIO (ELRANATAMAB) — FDA approvalelranatamab

    Sponsor: PFIZER INC. Form: SOLUTION. Route: INJECTION

    full page →elranatamab →fda approvals ↗
    ›Aug 14, 2023approval1094d agoAMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAMJEVITA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

    full page →AMJEVITA →fda approvals ↗
    ›Aug 15, 2023approval1093d agoVONJO (PACRITINIB CITRATE) — FDA approvalpacritinib

    Sponsor: SOBI. Form: CAPSULE. Route: ORAL

    full page →pacritinib →fda approvals ↗
    ›Aug 16, 2023approval1092d agoABRILADA (ADALIMUMAB-AFZB) — FDA approvalABRILADA

    Sponsor: PFIZER INC. Form: INJECTABLE. Route: INJECTION

    full page →ABRILADA →fda approvals ↗
    ›Aug 16, 2023approval1092d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION

    full page →RIFADIN →fda approvals ↗
    $PYPD4.7300-0.84%
    $PYPD4.7300-0.84%
    $PYPD4.7300-0.84%
    $NVS155.21-1.01%
    $PYPD4.7300-0.84%
    $NVS155.21-1.01%
    $PYPD4.7300-0.84%
    $NVS155.21-1.01%
    $PYPD4.7300-0.84%
    $PYPD4.7300-0.84%
    $PYPD4.7300-0.84%
    $PYPD4.7300-0.84%
    $PYPD4.7300-0.84%
    $PYPD4.7300-0.84%
    $JAZZ247.78-3.41%
    $LLY1223.99-0.64%
    $LLY1223.99-0.64%
    $VERX12.23+0.78%
    $VERX12.23+0.78%
    $VERX12.23+0.78%
    $VERX12.23+0.78%
    $VERX12.23+0.78%
    $VERX12.23+0.78%
    $VERX12.23+0.78%
    $RIGL41.29-0.89%
    $PFE26.63-1.57%
    $AMGN414.03-0.76%
    $PFE26.63-1.57%